Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Dasatinib
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Dasatinib 100mg tablets
0801050ANAAADAD
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 10mg/ml oral suspension
0801050ANAAAGAG
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 110.6mg tablets
0801050ANAAALAL
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 140mg tablets
0801050ANAAAEAE
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 15.8mg tablets
0801050ANAAAHAH
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 20mg tablets
0801050ANAAAAAA
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 39.5mg tablets
0801050ANAAAIAI
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 50mg tablets
0801050ANAAABAB
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 63.2mg tablets
0801050ANAAAJAJ
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 70mg tablets
0801050ANAAACAC
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 79mg tablets
0801050ANAAAKAK
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 80mg tablets
0801050ANAAAFAF
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Sprycel 100mg tablets
0801050ANBBADAD
|
Sprycel | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Sprycel 10mg/ml oral suspension
0801050ANBBAGAG
|
Sprycel | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Sprycel 140mg tablets
0801050ANBBAEAE
|
Sprycel | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Sprycel 20mg tablets
0801050ANBBAAAA
|
Sprycel | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Sprycel 50mg tablets
0801050ANBBABAB
|
Sprycel | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Sprycel 70mg tablets
0801050ANBBACAC
|
Sprycel | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Sprycel 80mg tablets
0801050ANBBAFAF
|
Sprycel | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 110.6mg tablets
0801050ANBCAEAL
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 15.8mg tablets
0801050ANBCAAAH
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 39.5mg tablets
0801050ANBCABAI
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 63.2mg tablets
0801050ANBCACAJ
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 79.0mg tablets
0801050ANBCADAK
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.